Диссертация (1154341), страница 45
Текст из файла (страница 45)
Biomarkers Prev. — 2013. — Vol. 22. — N. 11. — P. 1931–1943.174. Overexpression of p53 in the endometrial gland in postmenopausal women /Koi C., Hachisuga T., Murakami M., Kurita T. [et al.] // Menopause. — 2015. —N. 22(1). — P. 104-7.175. Pavlakis, K. PTEN-loss and nuclear atypia of EIN in endometrial biopsiescan predict the existence of a concurrent endometrial carcinoma / K. Pavlakis, I.
Messini,T. Vrekousis // Gynecologic Oncology. — 2010. —N. 119. — P. 516-519.176. Prediction of coexistent carcinomas risks by subjective EIN diagnosis andcomparison with WHO classification in endometrial hyperplasias / Yang Y.F., Liao Y.Y.,278Peng N.F., Li L.Q. [et al.] // Pathol.
Res. Pract. — 2012. — N. 208(12). — P. 708-12.177. Predictive ability of estrogen receptor (ER), progesterone receptor (PR),COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrialhyperplasia treated with LNG-IUS: a prospective cohort study / Gallos I.D., Devey J.,Ganesan R., Gupta J.K.
// Gynecol. Oncol. — 2013. — N. 130(1). — P. 58-63.178. Preoperative local staging of endometrial cancer: transvaginal sonographyvs. magnetic resonance imaging / Savelli L., Ceccarini M., Ludovisi M. [et al.] //Ultrasound Obstet. Gynecol. – 2008. – Vol. 31. — P. 560–566.179. Preoperative staging of endometrial cancer using TVS, MRI, andhysteroscopy / Ortoft G., Dueholm M., Mathiesen O., Hansen E.S.
[et al.] // Acta. Obstet.Gynecol. Scand. — 2013. — N. 92(5). — P. 536-45.180. Promoterhypermethylationofthetumor-suppressorgenesRASSF1A, GSTP1and CDH1 in endometrial cancer / Fiolka R., Zubor P., Janusicova V.,Visnovsky J. [et al.] // Oncol. Rep. — 2013. — N. 30(6). —P. 2878-86.181. Prospective study of the contribution of hydrosonography in the explorationof the uterine cavity / Malek-Mellouli M., Ben Amara F., Khaled N., Arfaoui R. [et al.]// Tunis Med. — 2012. — N. 90(10). — P.
702-7.182. PTEN Expression in endometrial biopsies as a marker of progression toendometrial carcinoma / Lacey J.V., George J., Mutter L. [et al.] // Cancer Res. —2008. — Vol. 68 (14). — P. 6014-6020.183. Quddus, M.R. Utility of PTEN expression of endometrial "surface epithelialchanges" and underlying atypical endometrial hyperplasia / Quddus M.R., Ologun B.A.,Sung C.J. // Int. J. Gynecol. Pathol.
— 2009. — N. 28(5). — P. 471-6.184. Rao, A.C. Immunohistochemical phosphor tensin tumor suppressor genestaining patterns in endometrial hyperplasia: a 2-year study / Rao A.C., Arya G.,Padma P.J. // Indian J. Pathol. Microbiol. — 2011. — N. 54(2). — P. 264-8.185. Relapse of endometrial hyperplasia after conservative treatment: a cohortstudy with long-term follow-up / Gallos I.D., Krishan P., Shehmar M., Ganesan R.
[et al.]// Hum. Reprod. — 2013. — N. 28(5). — P. 1231-6.186. Risk factor analysis of coexisting endometrial carcinoma in patients with279endometrial hyperplasia: a retrospective observational study of Taiwanese GynecologicOncology Group / Y.L. Chen [et al.] // J. Gynecol. Oncol. – 2013. – Vol.24, N 1.
– P. 1420.187. Risk factors for developing endometrial cancer after benign endometrialsampling / Torres M.L., Weaver A.L., Kumar S., Uccella S. [et al.] // Obstet. Gynecol. —2012. — N. 120(5). — P. 998-1004.188. Risk of malignancy in endometrial polyps in premenopausal andpostmenopausal women according to clinicopathologic characteristics / Costa-Paiva L.,Godoy C.E. Jr, Antunes A Jr, Caseiro J.D., Arthuso M. [et al.] // Menopause. — 2011. —N.
18(12). — P. 1278-82.189. Rižner, T.L. Estrogen biosynthesis, phase I and phase II metabolism, andaction in endometrial cancer / T.L. Rižner // Mol. Cell. Endocrinol. — 2013. — N. 5. —P. 124-39.190. Shevra, C.R. Cyclin D1 and Ki-67 expression in normal, hyperplastic andneoplastic endometrium / Shevra C.R., Ghosh A., Kumar M.
// J. Postgrad. Med. —2015. — N. 61(1). — P. 15-20.191. Vergote I. Should we screen for endometrial cancer? / Vergote I., Amant F.,Timmerman D. // Lancet Oncol. — 2011. — P. 12:4-5.192. Significance of abnormal sonographic findings in postmenopausal womenwith and without bleeding // J. Obstet. Gynaecol. Can. — 2011.
— N. 33(9). – P. 944–51.193. Sivridis, E. Endometrial stromal hyperplasia: an underrecognized condition /Sivridis E., Koutsougeras G., Giatromanolaki A. // Case Rep. Pathol. — 2013. — P.2040–82.194. Specifics of hormonal and energy balance in patients with hyperplasia andendometrial neoplasia with metabolic syndrome in the background / Chernyshova A.L.,Kolomiets L.A., Bochkarëva N.V., Kondakova I.V. // Vopr.
Onkol. — 2013. —N. 59(1). — P. 65-71.195. Squamous morules are functionally inert elements of premalignantendometrial neoplasia / Lin M.C., Lomol L., Baak J.P. [et al.] // Mod. Pathol. — 2009. —280N. 22. — P. 167-174.196. The accuracy of endometrial sampling in the diagnosis of patients withendometrial carcinoma and hyperplasia: a meta-analysis / Dijkhuizen F.P., Mol BW,Brцlmann HA, Heintz AP // Cancer. — 2000. — Vol. 15. — Iss.
89(8). — P. 1765–72.197. The fertility-sparing treatment in patients with endometrial atypicalhyperplasia and early endometrial cancer: a debated therapeutic option / Gadducci A.,Spirito N., Baroni E., Tana R. // Gynecol. Endocrinol. — 2009. — N.
25(10). – P. 68391.198. The prognostic value in tissue removed by curettage from FIGO stage 1 and2 endometrioid type endometrial cancer / Steinbakk A., Skaland I., Gudlaugsson E. [etal.] // American Journal of Obstetrics and Gynecology. — 2009. — N. 200. — P. 78.199. The role of hypertension, body mass index, and serum leptin levels inpatients with endometrial hyperplasia during premenopausal period / Balbi G.,Napolitano A., Seguino E., Scaravilli G.
[et al.] // Clin. Exp. Obstet. Gynecol. — 2012. —N. 39(3). — P. 321-325.200. Ultrasound and sonohysterography in the evaluation of abnormal vaginalbleeding / Miller J.C., Schiff I., Thrall J.H., Lee S.I. / J. Am. Coll. Radiol. — 2008. —Vol. 5.
— P. 1154-6.201. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-gradeendometrial cancer and disordered proliferative/benign hyperplastic endometrium byimprint cytology / Apostolou G., Apostolou N., Biteli M., Kavantzas N. [et al.] // Diagn.Cytopathol. — 2014. — N. 42(2). — P. 134-142.202. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata:an open-label study / Yerushalmi G. M., Gilboa Y., Jakobson-Setton A. [et al.] // Fertil.Steril. — 2014. — Vol.
101. — P. 496–500.203. Value of endometrial thickness measurement for diagnosing focalintrauterine pathology in women without abnormal uterine bleeding / Dreisler E.,Sorensen S.S., Ibsen P.H., Lose G. // Ultrasound Obstet. Gynecol.
— 2009. —N. 33(3). — P. 344-8.204. Yasue, A. Effects of tamoxifen on the endometrium and its mechanism of281carcinogenicity / Yasue A., Hasegawa K., Udagawa Y. // Hum. Cell. — 2011. —N. 24(2). — P. 65-73.205. Zaino, R.J. Reproducibility of the Diagnosis of Atypical EndometrialHyperplasia / Zaino R.J., Kanderer J., Trimble C.L. // Cancer. – 2006. – Vol. 106. –P. 804–811..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
